Science Explorer Back to mapMap
Discussion
Institution · Instituto Cardiovascular de Rosario

Most cited papers from Instituto Cardiovascular de Rosario

Instituto Cardiovascular de Rosario

What are the most cited papers from Instituto Cardiovascular de Rosario?

The most cited paper from Instituto Cardiovascular de Rosario is "Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome" (Gregory G. Schwartz et al., 2018), with 3,654 citations. Next come "Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease" (2,456) and "Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial" (2,067).

Showing 50 of 60 papers. Every paper with more than 71 citations is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome Gregory G. Schwartz et al. · New England Journal of Medicine Open access 7 Nov 2018 3,654
2 Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease John W. Eikelboom et al. · New England Journal of Medicine Open access 27 Aug 2017 2,456
3 Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial Christina Davies et al. · The Lancet Open access 5 Dec 2012 2,067
4 Prognostic value of grip strength: findings from the Prospective Urban Rural Epidemiology (PURE) study Darryl P. Leong et al. · The Lancet Open access 13 May 2015 1,905
5 Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease Deepak L. Bhatt, Michael J. Szarek, Bertram Pitt et al. · New England Journal of Medicine Open access 16 Nov 2020 1,206
6 Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial Alexandre Mebazaa, Beth A. Davison, Ovidiu Chioncel et al. · The Lancet Open access 7 Nov 2022 1,098
7 Tobacco use and risk of myocardial infarction in 52 countries in the INTERHEART study: a case-control study Koon Kang Teo, Stephanie Ôunpuu, Steven Hawken et al. · The Lancet Aug 2006 1,004
8 Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial Sonia S. Anand et al. · The Lancet Open access644 authors 10 Nov 2017 892
9 Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease Salim Yusuf et al. · New England Journal of Medicine Open access 2 Apr 2016 854
10 Effects of Aspirin Dose When Used Alone or in Combination With Clopidogrel in Patients With Acute Coronary Syndromes Ron J.G. Peters, Shamir R. Mehta, Keith A.A. Fox et al. · Circulation Open access 22 Sep 2003 704
11 Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease Eva Lonn et al. · New England Journal of Medicine Open access 2 Apr 2016 622
12 Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome Vera Bittner et al. · Journal of the American College of Cardiology Open access 2020 599
13 Metabolic Modulation of Acute Myocardial Infarction Rafael Dı́az, Ernesto Paolasso, Leopoldo Soares Piegas et al. · Circulation 24 Nov 1998 518
14 Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin Paul Moayyedi et al. · Gastroenterology Open access 29 May 2019 484
15 Global mortality variations in patients with heart failure: results from the International Congestive Heart Failure (INTER-CHF) prospective cohort study Hisham M Dokainish et al. · The Lancet Global Health Open access143 authors 3 May 2017 413
16 Association of the triglyceride glucose index as a measure of insulin resistance with mortality and cardiovascular disease in populations from five continents (PURE study): a prospective cohort study Patricio López‐Jaramillo et al. · The Lancet Healthy Longevity Open access 12 Dec 2022 393
17 Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease Salim Yusuf et al. · New England Journal of Medicine Open access 2 Apr 2016 378
18 Risk Factors for Acute Myocardial Infarction in Latin America Fernando Tomas Lanas, Álvaro Avezum, Leonelo E. Bautista et al. · Circulation Open access 5 Mar 2007 353
19 Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial Kausik K Ray et al. · The Lancet Diabetes & Endocrinology Open access1,703 authors Jul 2019 332
20 Anatomic crown width/length ratios of unworn and worn maxillary teeth in white subjects Pascal Magne, German O. Gallucci, Urs C. Belser · Journal of Prosthetic Dentistry Open access May 2003 251
21 Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syndrome J. Wouter Jukema, Michael J. Szarek, Laurien E. Zijlstra et al. · Journal of the American College of Cardiology Open access 18 Mar 2019 239
22 Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial Michael J. Szarek et al. · European Heart Journal Open access 24 Jul 2020 223
23 Blood-pressure reduction and cardiovascular risk in HOPE study Peter Sleight, Salim Yusuf, Janice M. Pogue et al. · The Lancet Dec 2001 221
24 Aneurysm Study of Pipeline in an Observational Registry (ASPIRe) David F Kallmes et al. · Interventional Neurology Open access 2016 212
25 Salt and cardiovascular disease: insufficient evidence to recommend low sodium intake Martin James O'Donnell et al. · European Heart Journal Open access 10 Jul 2020 209
26 Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome Gregory G. Schwartz, Philippe Gabríel Steg, Michael J. Szarek et al. · Circulation Open access 29 Mar 2020 193
27 Erectile Dysfunction Predicts Cardiovascular Events in High-Risk Patients Receiving Telmisartan, Ramipril, or Both Michael C Böhm, Magnus Baumhäkel, Koon Kang Teo et al. · Circulation Open access 16 Mar 2010 191
28 Heart Failure in Africa, Asia, the Middle East and South America: The INTER-CHF study Hisham M Dokainish et al. · International Journal of Cardiology Open access 2 Dec 2015 190
29 Design and baseline characteristics of participants in the R esearching cardiovascular E vents with a W eekly IN cretin in D iabetes ( REWIND ) trial on the cardiovascular effects of dulaglutide Hertzel C. Gerstein et al. · Diabetes Obesity and Metabolism Open access 2 Jun 2017 188
30 Sensible approaches for reducing clinical trial costs Eric L. Eisenstein, Rory Collins, Beena S Cracknell et al. · Clinical Trials Feb 2008 181
31 Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events Michael J. Szarek et al. · Journal of the American College of Cardiology Open access 11 Nov 2018 175
32 Hepatitis A Virus in Stool During Clinical Relapse Maria H. Sjögren, Hugo Tanno, Oscar H. Fay et al. · Annals of Internal Medicine Feb 1987 174
33 Rationale, Design and Baseline Characteristics of Participants in the C ardiovascular O utco m es for P eople Using A nticoagulation S trategie s (COMPASS) Trial Jackie Bosch et al. · Canadian Journal of Cardiology Open access 8 Jun 2017 161
34 Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes Mellitus and Cardiovascular Disease Deepak L. Bhatt et al. · Circulation Open access 28 Mar 2020 157
35 Pantoprazole to Prevent Gastroduodenal Events in Patients Receiving Rivaroxaban and/or Aspirin in a Randomized, Double-Blind, Placebo-Controlled Trial Paul Moayyedi et al. · Gastroenterology Open access 2 May 2019 156
36 Fixed-dose combination therapies with and without aspirin for primary prevention of cardiovascular disease: an individual participant data meta-analysis Philip G. Joseph et al. · The Lancet Review 29 Aug 2021 152
37 Effect of Alirocumab on Mortality After Acute Coronary Syndromes Philippe Gabríel Steg et al. · Circulation Open access 23 May 2019 150
38 HbA1c Change and Diabetic Retinopathy During GLP-1 Receptor Agonist Cardiovascular Outcome Trials: A Meta-analysis and Meta-regression Mary Angelyn Bethel, Rafael Ugarriza Díaz, Noelia Castellana et al. · Diabetes Care ReviewOpen access 14 Dec 2020 149
39 Psychosocial Risk Factors and Cardiovascular Disease and Death in a Population-Based Cohort From 21 Low-, Middle-, and High-Income Countries Ailiana Santosa et al. · JAMA Network Open Open access 15 Dec 2021 146
40 Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol Gregory G. Schwartz et al. · Journal of the American College of Cardiology Open access1,752 authors 26 Jul 2021 146
41 Association of Sitting Time With Mortality and Cardiovascular Events in High-Income, Middle-Income, and Low-Income Countries Sidong Li et al. · JAMA Cardiology Open access 15 Jun 2022 134
42 Effect of Alirocumab on Stroke in ODYSSEY OUTCOMES J. Wouter Jukema, Laurien E. Zijlstra, Deepak L. Bhatt et al. · Circulation Open access 11 Nov 2019 133
43 Joint association of urinary sodium and potassium excretion with cardiovascular events and mortality: prospective cohort study Martin James O'Donnell et al. · BMJ Open access 13 Mar 2019 133
44 Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab Emil Hagström et al. · Circulation Open access1,735 authors 29 Aug 2022 126
45 Clinical Efficacy and Safety of Alirocumab After Acute Coronary Syndrome According to Achieved Level of Low-Density Lipoprotein Cholesterol Gregory G. Schwartz, Philippe Gabríel Steg, Deepak L. Bhatt et al. · Circulation Open access 13 Jan 2021 114
46 Assessment of Omecamtiv Mecarbil for the Treatment of Patients With Severe Heart Failure Gary Michael Felker, Scott David Solomon, Brian Lee Claggett et al. · JAMA Cardiology Open access 17 Oct 2021 108
47 Stroke Risk and Efficacy of Apixaban in Atrial Fibrillation Patients with Moderate Chronic Kidney Disease John W. Eikelboom, Stuart J. Connolly, Peggy Gao et al. · Journal of Stroke and Cerebrovascular Diseases 19 Jul 2012 105
48 Effects of Short-Term Continuous Positive Airway Pressure on Myocardial Sympathetic Nerve Function and Energetics in Patients With Heart Failure and Obstructive Sleep Apnea Allison Barbara Hall, María Cecilia Ziadi, Judith A. Leech et al. · Circulation 4 Jul 2014 97
49 Effect of alirocumab on cardiovascular outcomes after acute coronary syndromes according to age: an ODYSSEY OUTCOMES trial analysis Peter Sinnaeve et al. · European Heart Journal Open access 29 Oct 2019 90
50 Urbanization and physical activity in the global Prospective Urban and Rural Epidemiology study Kwadwo Boakye et al. · Scientific Reports Open access 6 Jan 2023 89

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.